Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 1
2022 4
2023 4
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.
Benatar M, Wuu J, Huey ED, McMillan CT, Petersen RC, Postuma R, McHutchison C, Dratch L, Arias JJ, Crawley A, Houlden H, McDermott MP, Cai X, Thakur N, Boxer A, Rosen H, Boeve BF, Dacks P, Cosentino S, Abrahams S, Shneider N, Lingor P, Shefner J, Andersen PM, Al-Chalabi A, Turner MR; Attendees of the Second International Pre-Symptomatic ALS Workshop. Benatar M, et al. Nat Rev Neurol. 2024 Jun;20(6):364-376. doi: 10.1038/s41582-024-00961-z. Epub 2024 May 20. Nat Rev Neurol. 2024. PMID: 38769202 Free PMC article. Review.
Defining pre-symptomatic amyotrophic lateral sclerosis.
Benatar M, Turner MR, Wuu J. Benatar M, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):303-309. doi: 10.1080/21678421.2019.1587634. Epub 2019 Mar 20. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 30892087 Free PMC article. Review.
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD.
Benatar M, Heiman-Patterson TD, Cooper-Knock J, Brickman D, Casaletto KB, Goutman SA, Vinceti M, Dratch L, Arias JJ, Swidler J, Turner MR, Shefner J, Westeneng HJ, van den Berg LH, Al-Chalabi A; Attendees of the Workshop on Guidance for Clinical Care of People Living with a Pathogenic Variant At-Risk for ALS and FTD. Benatar M, et al. J Neurol Neurosurg Psychiatry. 2025 Jan 31;96(3):e334339. doi: 10.1136/jnnp-2024-334339. Online ahead of print. J Neurol Neurosurg Psychiatry. 2025. PMID: 39572211 Free PMC article. Review.
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.
Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR; First International Pre-Symptomatic ALS Workshop. Benatar M, et al. Brain. 2022 Mar 29;145(1):27-44. doi: 10.1093/brain/awab404. Brain. 2022. PMID: 34677606 Free PMC article.
Identification of a presymptomatic and early disease signature for Amyotrophic Lateral Sclerosis (ALS): protocol of the premodiALS study.
Tzeplaeff L, Galhoz A, Meijs C, Gomes LC, Kovac A, Menzel A, Değirmenci H, Alaamel A, Kaya HC, Çelik AG, Dinçer S, Korucuk M, Karaüzüm SB, Bayraktar E, Çiftçi V, Bilge U, Koç F, Demleitner AF, Buchberger A, von Heynitz R, Gmeiner V, Knellwolf C, Mouzouri M, Wuu J, Başak AN, Andersen PM, Kohlmayer F, Ashton NJ, Kuban W, Lenz C, Rogers ML, Zilka N, Corcia P, Lerner Y, Weber M, Koprusakova MT, Uysal H, Benatar M, Menden MP, Lingor P. Tzeplaeff L, et al. medRxiv [Preprint]. 2025 May 27:2025.05.27.25328387. doi: 10.1101/2025.05.27.25328387. medRxiv. 2025. PMID: 40492096 Free PMC article. Preprint.
Neurofilaments in pre-symptomatic ALS and the impact of genotype.
Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. Benatar M, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):538-548. doi: 10.1080/21678421.2019.1646769. Epub 2019 Aug 21. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31432691 Free PMC article.
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.
McMillan CT, Wuu J, Rascovsky K, Cosentino S, Grossman M, Elman L, Quinn C, Rosario L, Stark JH, Granit V, Briemberg H, Chenji S, Dionne A, Genge A, Johnston W, Korngut L, Shoesmith C, Zinman L; Canadian ALS Neuroimaging Consortium (CALSNIC); Kalra S, Benatar M. McMillan CT, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):517-526. doi: 10.1080/21678421.2022.2039713. Epub 2022 Mar 7. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 35253557 Free PMC article.
A roadmap to ALS prevention: strategies and priorities.
Benatar M, Goutman SA, Staats KA, Feldman EL, Weisskopf M, Talbott E, Dave KD, Thakur NM, Al-Chalabi A. Benatar M, et al. J Neurol Neurosurg Psychiatry. 2023 May;94(5):399-402. doi: 10.1136/jnnp-2022-330473. Epub 2023 Jan 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36690429 Free PMC article. No abstract available.
17 results